<DOC>
	<DOCNO>NCT00009698</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill cancer cell . PURPOSE : Phase I trial study effectiveness interleukin-2 treat child undergone bone marrow transplantation acute myeloid leukemia .</brief_summary>
	<brief_title>Interleukin-2 Treating Children Who Have Undergone Bone Marrow Transplantation Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose interleukin-2 autologous bone marrow transplantation pediatric patient acute myeloid leukemia . II . Determine toxic effect regimen patient . OUTLINE : This dose escalation study . Patients receive interleukin-2 ( IL-2 ) subcutaneously day 1-7 , 9-14 , 16-22 . On day 8 15 , patient receive IL-2 IV 2 hour . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Cohorts 6-9 patient receive escalate dos IL-2 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 2 9 patient experience dose-limiting toxicity . Patients follow every 6 month 4 year annually thereafter . PROJECTED ACCRUAL : A total 6-27 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) Must receive autologous bone marrow stem cell transplantation AML within past 28 100 day Evidence marrow engraftment Absolute neutrophil count least 500/mm3 least 2 consecutive day Platelet count least 20,000/mm3 without transfusion support 3 day Documented M1 M2 bone marrow within past 7 day PATIENT CHARACTERISTICS : Age : Under 22 diagnosis Performance status : Karnofsky 50100 % Life expectancy : At least 8 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 mg/dL SGPT great 2 time normal Renal : Creatinine normal OR Glomerular filtration rate least 70 mL/min Cardiovascular : Shortening fraction least 27 % OR Ejection fraction great 50 % No evidence active cardiac disease electrocardiogram Pulmonary : No evidence active pulmonary disease chest xray Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologic deficit due CNS disease must stable within past 4 week No active viral , bacterial , invasive fungal infection No fever No prior hypersensitivity interleukin2 No great grade 2 mucosal toxicity PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 3 day since prior growth factor intravenous immunoglobulin No concurrent cytokine growth factor No concurrent intravenous immunoglobulin Chemotherapy : No concurrent chemotherapy No concurrent methotrexate IV intrathecally Endocrine therapy : At least 3 day since prior corticosteroid No concurrent corticosteroid ( except premedication document severe transfusion reaction ) Radiotherapy : Not specify Surgery : Not specify Other : At least 3 day since prior pentoxifylline amphotericin B No concurrent pentoxifylline No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
</DOC>